Antifungal Peptides and Proteins to Control Toxigenic Fungi and Mycotoxin Biosynthesis

Abstract

The global challenge to prevent fungal spoilage and mycotoxin contamination on food and feed requires the development of new antifungal strategies. Antimicrobial peptides and proteins (AMPs) with antifungal activity are gaining much interest as natural antifungal compounds due to their properties such as structure diversity and function, antifungal spectrum, mechanism of action, high stability and the availability of biotechnological production methods. Given their multistep mode of action, the development of fungal resistance to AMPs is presumed to be slow or delayed compared to conventional fungicides. Interestingly, AMPs also accomplish important biological functions other than antifungal activity, including anti-mycotoxin biosynthesis activity, which opens novel aspects for their future use in agriculture and food industry to fight mycotoxin contamination. AMPs can reach intracellular targets and exert their activity by mechanisms other than membrane permeabilization. The mechanisms through which AMPs affect mycotoxin production are varied and complex, ranging from oxidative stress to specific inhibition of enzymatic components of mycotoxin biosynthetic pathways. This review presents natural and synthetic antifungal AMPs from different origins which are effective against mycotoxin-producing fungi, and aims at summarizing current knowledge concerning their additional effects on mycotoxin biosynthesis. Antifungal AMPs properties and mechanisms of action are also discussed.

1. Introduction

Mycotoxins are toxic secondary metabolites produced by filamentous fungi in crops or during storage, transport and processing of food and feed commodities, which pose serious health risks for both humans and animals [1]. The trend of mycotoxin contamination in food and feed has reached alarming levels. According to a report of the Food and Agriculture Organization of the United Nations (FAO), 25% of global agricultural products are contaminated by mycotoxins each year [2]. However, recent data indicate that global mycotoxin occurrence in crops is much higher [3]. Apart from the serious health problems, significant economic losses are associated with the impact of mycotoxins on human health, animal welfare and productivity, as well as both domestic and international trade [4,5]. Approximately 400 mycotoxins produced by over 300 fungal species have been identified. Nevertheless, a limited number of toxins are generally considered important in food safety [3]. Aspergillus, Fusarium and Penicillium are the major mycotoxin-producing fungi, and the most important classes of mycotoxins include aflatoxins (AFs), ochratoxin A (OTA), deoxynivalenol (DON), fumonisins (FUM), zearalenone (ZEA), T-2 toxin, HT-2 toxin, citrinin (CIT) and patulin (PAT) [6]. All of them are regulated after a thorough risk assessment procedure [7,8]. In addition, emerging mycotoxins are attracting increasing interest among the scientific community, such as the Fusarium mycotoxins enniatins (ENs), beauvericin (BEA), moniliformin (MON), fusaproliferin (FUS), the Aspergillus toxins sterigmatocystin (STE) and emodin (EMO), and the Alternaria toxins alternariol (AOH) and tenuazonic acid (TeA) [9]. Finally, the risk is usually considered for each single mycotoxin; however, mycotoxin contamination rather corresponds to the simultaneous presence of several mycotoxigenic species and/or species able to produce several mycotoxins [10].

Consumption of major mycotoxin-containing food or feed may induce adverse health effects in humans or animals. Aspergillus species, specially Aspergillus flavus and Aspergillus parasiticus are the main producers of AFs, which are considered the most toxic mycotoxins with hepatotoxic, mutagenic, genotoxic, teratogenic and immunosuppressive effects, through multiple mechanisms [11]. In particular, AF1 is the most potent natural carcinogen known [12]. OTA, produced by Aspergillus and Penicillium species, is a mycotoxin with nephrotoxic, carcinogenic, immunotoxic, genotoxic and teratogenic effects that has been classified under class 2B carcinogens [13]. OTA has been suspected as a cause of various human nephropathies since the 1970s including Balkan Endemic Nephropathy (BEN) [14]. OTA seems to be involved in the inhibition of protein synthesis and energy production, and in induction of oxidative stress [15]. ZEA is mainly produced by Fusarium graminearum and, to a lesser extent, by other Fusarium species. The main threat to human and animal health of ZEA is its xenogeneic action. ZEA has the ability to bind to estrogen receptors, causing its bioaccumulation. This leads to hormonal balance disorders, and diseases associated with the reproductive system [16]. The trichothecenes (TCT) constitute a large family of mycotoxins including DON and the T-2 and HT-2 toxins, which are produced by Fusarium species. TCT are toxic to humans and animals, and affect the gastrointestinal tract, skin, kidney, liver, and immune and hematopoietic progenitor cellular systems [17]. The mechanism of action mainly consists of the inhibition of protein synthesis and oxidative damage to cells, followed by the disruption of nucleic acid synthesis and ensuing apoptosis. TCT have a spectrum of adverse effects including emesis, anorexia, growth retardation, neuroendocrine changes, immunotoxicity, and a reduction in food consumption in various animal species. FUM are predominantly produced by Fusarium moniliforme and Fusarium proliferatum. They affect animals by interfering with sphingolipid metabolism, but he extent to which FUM impact human health remains poorly understood [18]. Penicillium citrinum is the major producer of CIT, which is associated with yellowed rice disease in Japan and acts as a nephrotoxin in all animal species tested [19]. Finally, PAT, mostly produced by Penicillium expansum, causes neurotoxic, immunotoxic, carcinogenic, teratogenic and mutagenic effects in cell cultures, but evidence for chronic toxicity in humans is indirect and inconclusive [19].

A wide range of physical, chemical and biological methods have been applied to control mycotoxin contamination including green and emerging technologies such as ionizing and non-ionizing radiation, cold plasma, pulsed light, ultrasound, pulsed electric field and high-pressure processing [1,20,21]. Among them, the use of antifungal compounds continues to be one of the most effective strategies. The first step to fight fungal contamination is the application of fungicides in the field and during postharvest of fruits and vegetables. However, the indiscriminate and abusive use of synthetic fungicides, which have a specific mode of action towards a single target in the fungal pathogens, has resulted in the development of resistant strains [20]. Fungicide resistance has been reported in toxigenic species from Aspergillus, Penicillium, Fusarium and Alternaria genera [21]. Since mycotoxins are produced as secondary metabolites, their biosynthesis is not essential for the growth of mycotoxin-producing fungi. Therefore, specific mycotoxin-production inhibitors that do not affect fungal growth may be useful for mycotoxin control without incurring rapid spread of resistant fungal strains. Additionally, increasing evidence suggests that fungicides might not be that efficient at reducing toxin production, because in certain conditions they may act as stress factors resulting in the induction of toxin biosynthesis. Sublethal doses of some fungicides could lead to the stimulation of mycotoxin production by several Fusarium species [22,23]. On the other hand, their repeated application may lead to accumulation and contamination of various ecosystems with long-lasting negative impact on plants, soil and water, consequently affecting human and animal health. Fungicides have recently been linked to cancer, respiratory and hormone imbalance diseases depending on the level of exposure [24,25,26]. Driven by the opinion of consumers, who perceive pesticides as a threat, and the vast amount of research supporting this view, regulators have approved laws that result in either banning or restricting their use by imposing lower maximum residue limits [27,28].

In this context, there is a significant interest in the development of alternative, environmentally friendly methods for the control of fungal pathogens and toxigenic fungi. During food processing and storage, chemical preservatives with more natural characteristics such as salts of organic acids (e.g., benzoate, propionate and sorbate) are used to inhibit fungal growth [29,30]. They show some advantages such as a wide spectrum activity, low toxicity and relatively low cost, and are classified as food additives or generally recognized as safe (GRAS) compounds [31]. However, high concentrations of these compounds are needed to control fungal growth, bringing associated potential organoleptic changes. Furthermore, treatments with salts of organic acids could also increase mycotoxin biosynthesis by toxigenic fungi. For instance, sodium propionate and potassium sorbate were able to activate the Penicillium verrucosum OTA polyketide synthase gene [32].

New antifungal strategies are needed and current interests are focused on novel antifungal agents with properties and mechanisms of action different from existing ones. Ideally, newly developed compounds should also combine major aspects such as sustainability, stability, high efficacy, limited toxicity and low costs of production [33]. Antimicrobial proteins and peptides (AMPs) with antifungal activity meet the desired requirements to fight fungal contaminations and have gained strong interest as alternative control strategies [34,35,36,37]. Their future applicability is greatly supported by their high stability, the lack of cytotoxic effect on mammals and plants [37], and the very unlikely event of resistance development. Moreover, antifungal AMPs allow crop improvement by the generation of transgenic plants with enhance resistance against phytopathogenic fungi, and therefore could also control mycotoxin contamination [38,39].

AMPs have gained interest in research and have been the focus of recent reviews, especially about their antimicrobial action [34,40,41]. Additionally, features such as high selectivity and thermostability have attracted the interest of the food industry towards the application of AMPs in food preservation [33,42,43,44]. Apart from that, the number of reports that document new additional functions of AMPs beyond their antimicrobial activity is constantly increasing [45,46]. Regarding antifungal activity, additional functions are associated to different biological processes including sporulation and production of secondary metabolites such as mycotoxins [45,46].

This review includes the main features of antifungal AMPs and gives an overview of AMPs from different origins that exhibit antifungal activity against mycotoxin-producing fungi. AMPs with anti-mycotoxin biosynthesis functions are also reviewed and their mode of action is discussed. Finally, we evaluate future perspectives and potential applications of these proteins and peptides.

2. General Properties and Characteristics of Antimicrobial Peptides and Proteins (AMPs)

AMPs are small bioactive proteins or peptides, mostly cationic, that are naturally produced by nearly all living organisms. They primarily act as components of their innate immune system, becoming the first-line defense against microbial attacks in higher organisms. Additionally, AMPs might be produced as competition strategies by microorganisms to limit the growth of other competitors [40,47]. AMPs are present in bacteria, fungi, plants, invertebrates and vertebrates [37,48,49], and are known for their broad spectrum activity against bacteria, fungi, viruses, protozoa and/or even cancer cells [50,51]. Remarkably, there are AMPs particularly effective against fungi [37,52,53] and some of them show antifungal activity against mycotoxin-producing fungi.

AMPs are basically synthesized by two biosynthetic routes. Most are ribosomally encoded AMPs, while other AMPs are generated by non-ribosomal peptide synthases (NRPSs). The latter are mainly found in bacteria, in particular Actinomycetes and Bacilli [54]. The NRPS-generated AMPs are characterized by the incorporation of nonproteinogenic amino acids into the sequence and are often heavily modified through hydroxylation, glycosylation, lipidation, and cyclization [55].

Characterization of the mode of action of AMPs is essential to improve their activity, avoid development of resistance, and accelerate their use as therapeutics or food preservatives. There is a significant volume of information available on the general mechanisms of action of AMPs (Figure 1) [56,57,58,59,60]. In general, AMPs can act at multiple cell targets. Cationic AMPs physically interact with the negatively charged microbial envelopes [61]. However, electrostatic interactions cannot entirely explain other observed activity of AMPs, and thus, specific component of membrane envelopes seem to aid AMP interactions. In fungi, the cell wall plays a key role in the internalization and activity of several AMPs. Different AMPs has been reported to affect fungal cell wall by inhibiting β-glucan or chitin synthesis, and targeting mannoproteins from the cell wall in sensitive fungi [52].

Figure 1.

General mode of action of antifungal AMPs.

Once AMPs diffuse through the cell wall, they face the cell membrane. Any alteration of the plasma membrane may impact the distribution, regulation, activity and signaling function of membrane proteins, with adverse effects on fungal cells. Once the interaction occurs, AMPs are classified as membrane-disruptive or membrane non-disruptive. The cationic and amphipathic character of most AMPs allow the disruption of lipid cell membranes causing pore formation, loss of biophysical properties and cell killing [56,62]. However, peptides acting through a lytic mechanisms are often highly toxic to different cell types [59]. Therefore, AMPs with non-lytic mechanism such as the cell penetrating peptides (CPPs) are preferred [57]. Once inside the cells, AMPs may target multiple processes. Common patterns of AMPs are the disruption of intracellular ion homeostasis, disruption of internal organelles such as mitochondria, (in)activation of signaling cascades, induction of reactive oxygen species (ROS) or apoptotic markers, disruption of cell cycle, DNA damage, and transcription and protein biosynthesis alteration [45,59] (Figure 1).

AMPs can also affect less commonly reported processes such as the production of secondary metabolites, including mycotoxins, which opens novel aspects for their future use in crops, postharvest and food processes. However, little is known about their mechanisms affecting mycotoxin biosynthesis in filamentous fungi. Studies on the effect on mycotoxin biosynthesis are restricted mainly to cyclopeptides derived from bacteria such as lipopeptides, small cysteine rich proteins (CRPs) which include defensins and antifungal AMPs of fungal origin (AFPs), and non-natural synthetic peptides. The main characteristics of these antifungal AMPs are summarized below.

Cyclopeptides derived from microorganisms contain both proteinogenic and unnatural amino acid residues [41]. Among them, lipopeptides produced by members of the Bacillus genus are compounds of great interest due to their activity against mycotoxin-producing fungi. These low molecular weight secondary metabolites have a broad range of activity, high biodegradability and low toxicity and are usually synthetized through NRPSs. They are composed of a hydrophilic cyclic peptide structure of 7–10 amino acids linked to a hydrophobic fatty acid chain with 13–19 carbon atoms. These compounds maintain their activities at high temperatures and different pH values; additionally, they resist peptidase and protease treatments [63,64]. Lipopeptides are classified into three major families according to their amino acid sequence: iturins which are heptapeptides with a β-amino fatty acid; fengycins which are decapeptides with a β-hydroxy fatty acid chain and surfactins, heptapeptides containing a β-hydroxy fatty acid tail with synergistic action with the two previous groups.

Defensins found in mammals, insects and plants (45–54 amino acids in length) form by far, the largest family of CRPs and are highly active against a large range of microorganisms. Regardless of the origin, defensins are structurally similar peptides. They have β-hairpin structures, stabilized by three/four disulfide bonds, but their sequences are divergent and show different activities, which include antifungal, antibacterial, or antitumoral activities [48]. Another CRP group of interest comprises of the AMPs of fungal origin, the so-called AFPs. AFPs are small (45–64 amino acids) and cationic defensin-like proteins that are produced and secreted to the culture medium by filamentous ascomycetes, mostly from the genera Aspergillus and Penicillium, and exhibit antifungal activity [45]. Several of these proteins have activity towards fungal plant pathogens with minimal inhibitory concentration (MIC) in the low micromolar range [65,66,67], and no toxicity to bacterial, plant or animal cells [67,68,69]. AFPs fold into five β-strands forming two packed β-sheets that share a common interface, and typically have six cysteine residues, forming three disulfide bonds [70,71]. A three-dimensional peptide signature, called the ɣ-core (Gly-X-Cys-X_3–9-Cys), is present in virtually all defensins and AFPs [72].

Finally, the synthetic peptides with antifungal activities should also be noted. Synthetic AMPs are designed de novo based on the properties of natural AMPs or identified using combinatorial approaches. Peptide analogs of natural AMPs have been synthesized with substituted, deleted, or extended amino acids. Synthetic analogs have been produced through the modification of amino acid sequence, either by shortening the sequence to determine minimal antimicrobial motifs, or by extending peptide length, even by fusion of fragments from different peptides [73]. These approaches, mainly directed to improve the antifungal activity, reduce toxicity to non-target cells and increase stability against degradation; additionally, they have contributed substantially to increasing the number and diversity of known AMPs [37,74,75,76].

3. Effects of Distinct AMPs on Growth of Mycotoxin-Producing Fungi

Mycotoxins are secondary metabolites that are normally produced at the end of the exponential growth phase. Thus, mycotoxin production is generally thought to be correlated with the growth rate of producing fungi. Therefore, inhibiting fungal growth is often considered as the most effective strategy to prevent mycotoxin production.

Here we describe those antifungal AMPs that show activity against common mycotoxin-producing fungi, such as Alternaria, Aspergillus, Penicilllium and Fusarium species. These peptides have distinct and phylogenetically distant origins, ranging from microorganisms, to plants and mammals, as well as synthetic rationally designed peptides.

3.1. Antifungal AMPs from Microorganisms

A wide diversity of antifungal AMPs, produced by bacteria, are able to control fungal growth in vitro and in vivo. They mainly include antifungal AMPs produced by lactic acid bacteria (LAB), as well as species from the Streptomyces, Bacillus and Burkholderia genera, which are particularly active against fungal species belonging to the Aspergillus, Penicillium and Fusarium genera, but also to other species such as those from the Byssochlamys genus (Table 1). As examples of applications in vivo, the antifungal protein YvgO isolated from Bacillus thuringiensis, was able to extend the shelf-life of different fruit juices inoculated with the PAT producer Byssochlamys fulva, and provided a complimentary measure of protection in UV-treated fruit juices [77]. On the other hand, a high antifungal activity of peptides generated by L. plantarum TE10 was reported against A. flavus. Results demonstrated promising application of the peptide mixture as bio-control agent to prevent the growth of A. flavus in maize [78]. Relevant bacterial AMPs with effect on mycotoxin biosynthesis are highlighted in the next section.

Table 1.

Microbial antifungal proteins and peptides with activity against mycotoxin-producing fungi.

Origin	Peptide	Target Fungi	Ref.
Bacteria
Bacillus amyloliquefaciens	Flagellin	F. oxysporum, A. niger	[85]
B. subtilis	Fengycins	F. oxysporum	[86]
B. subtilis	Iturin A	Aspergillus spp., Fusarium spp., Penicilium spp.	[87]
B. thuringiensis	YvgO	B. fulva	[77]
Burkholderia cepacia	Cepacidines	A. niger	[88]
Enterococcus durans	Duracin	F. culmorum	[89]
Lactic acid bacteria	Bacteriocins	A. parasiticus, P. expansum	[90,91]
Lactobacillus brevis AM7	Peptides	P. roqueforti	[92]
L. paracasei	Bacteriocin F1	P. glaucum, A. niger, A. flavus	[93]
L. plantarum	LR/14	A. niger, P. chrysogenum	[94]
L. plantarum	FPSHTGMSVPPP	Aspergillus spp., P. roqueforti	[95]
L. plantarum TE10	Peptides MIX	A. flavus	[78]
Streptomyces spp.	C/33-6	F. graminearum	[96]
S. tendae	Nikkomycin Z	Aspergillus spp., Fusarium spp., Penicilium spp.	[97]
S. tendae Tu901	AFP1	A. fumigatus	[98]
Fungi
Aspergillus giganteous	AFP	Fusarium spp.	[99]
A. clavatus	AcAFP	F. oxysporum, F. solani	[100]
A. clavatus	AcAMP	F. oxysporum, F. solani	[101]
A. niger	Anafp	A. flavus, F. oxysporum, F. solani	[65]
Fusarium graminearum	FgAFP	F. verticilloides, F. proliferatum	[102]
Emericellopsis alkalina	Emericellipsin A	A.niger, A. flavus	[103]
Monascus pilosus	MAFP1	Fusarium spp.	[104]
Neosartoria fischeri	NFAP	A. nidulans, F. graminearum	[105]
N. fischeri	NFAP2	A. nidulans	[106]
Penicillium citrinum	PcPAF	F. oxysporum	[107]
P. chrysogenum	PAF	F. oxysporum, A. flavus	[108]
P. chrysogenum	PgAFP/PAFB	F. oxysporum, A. flavus	[81,109]
P. chrysogenum	Pc-Arctin/PAFC	A. longipes, B. spectabilis	[66,110]
P. digitatum	PdAfpB	F. oxysporum, P. expansum	[82,111]
P. expansum	PeAfpA	A. alternata, Aspergillus spp., Byssochlamys spp., Fusarium spp., Penicillium spp.	[82]
P. expansum	PeAfpB	Alternaria spp., Aspergillus spp., Byssochlamys spp., Fusarium spp., Penicillium spp.	[82]
P. expansum	PeAfpC	A. flavus, Byssochlamys spp.	[82]

Fungi have a complex repertoire of AFPs that differ in amino acid composition and sequence [37,42,69,79,80]. Several studies already indicated that some of the most hazardous mycotoxin-producing fungi are sensitive to AFPs (Table 1). Of interest are those studies showing antifungal activity in a wide range of mycotoxin producers and differences in susceptibility to AFPs among the fungal genera and species. Delgado et al. [81] evaluated the antifungal activity of PgAFP from P. chrysogenum against toxigenic fungi commonly found in dry-ripened foods. PgAFP retarded the growth of most fungi tested and the main mycotoxin-producing fungi analyzed, such as those producing AFs (A. flavus and Aspergillus parasiticus), OTA (A. carbonarius, A. ochraceus, and P. nordicum), ST (A. versicolor) and PAT (P. expansum and P. griseofulvum). Recently, AFPs from P. digitatum (PdAfpB) and P. expansum (PeAfpA, PeAfpB and PeAfpC), were tested against a representative panel of mycotoxin-producing fungi belonging to the genera Alternaria, Aspergillus, Byssochlamys, Fusarium and Penicillium [82]. These were previously reported to produce up to 26 different mycotoxins. AFPs showed significant activity against most of the mycotoxigenic fungi tested, in particular PeAfpA. PeAfpC showed powerful inhibition against Byssochlamys spectabilis (PAT producer), which is an important spoilage fungus in pasteurized food products, such as fruit juices and canned fruits [83]. Differences in susceptibility to AFPs were observed among fungal genera. In general, Aspergillus, Byssochlamys and Penicillium were more sensitive than the Fusarium genus. Moreover, the antifungal effect of AFPs also differed within the same species [81,82,84]. Further studies on susceptibility and resistance of fungal species including more strains from each species are needed to elucidate antifungal specificities of AFPs.

Remarkably, the efficacy of some AFPs in in vivo experiments has been proven. For instance, PgAFP efficiently reduced counts of A. flavus inoculated on a dry-fermented sausage [81], while A. giganteus AFP protected tomato seedlings from vascular wilt disease caused by F. oxysporum f. sp. lycopersici [99]. Also PdAfpB and PeAfpA controlled the growth of P. expansum in apple fruits [112].

3.2. Antifungal AMPs from Plants

Plant AMPs are constitutively expressed in both plant storage and reproductive organs, but they can also be locally or systematically induced during plant defense response [113]. Antifungal AMPs have been isolated from a wide variety of plant species, and classified by amino acid sequence, position and number of cysteine residues involved in the disulfide bridges, and/or function to families [37,114]. A large list of these families show inhibitory activity against mycotoxin-producing fungi (Table 2). It is noteworthy that, contrary to that described for fungal AFPs, most fungi sensitive to plant antifungal AMPs are Fusarium species, especially F. culmurum, F. graminearum, F. oxysporum and F. solani. However, other toxigenic fungal species from Aspergillus (A. flavus, A. niger), Penicillium (P. expansum) and Alternaria (A. alternata, A. solani) have been successfully inhibited by antifungal AMPs from plants [37,43,114]. As a practical example, we highlight the application of the onion (Allium cepa) defensin Ace-AMP1on tomato leaves. Treated leaves showed enhance resistance to the tomato pathogen A. solani (TeA and AOH producer), making this AMP a promising fungicide to be used in agriculture [115] (Table 2).

Table 2.

Plant antifungal proteins and peptides with activity against mycotoxin-producing fungi.

Peptide	Origin	Target Fungi	Ref.
Defensins
Ace-AMP1	Allium cepa	F. solani, F. oxysporum	[115]
Dm-AMP1	Dahlia merkii	Fusarium spp.	[116]
MsDef1	Medicago sativa	F. graminearum	[117]
MtDef4	M. truncatula	F. graminearum	[118]
NaD1, NaD2	Nicotiana alata	F. graminearum, F. oxysporum	[119]
OefDef1.1	Olea europea	Fusarium spp.	[120]
PvD1	Phaseolus vulgaris	F. solani, F. oxysporum	[121]
Rs-AFP2	Raphanus sativus	A. flavus, F. solani	[122]
TPP3	N. tabacum	Fusarium spp.	[122]
Hevein-type
Ee-CBP	Euonymus europaeus	F. culmorum	[123]
GAFP	Ginkgo bilolba	F. graminearum	[124]
SmAMP3	Stellariamedia	F. solani	[125]
Vaccatides	Vaccaria hispanica	Fusarium spp.	[126]
WAMP-1a and b	Triticum aestivum	F. moniliforme	[127]
Napin
BoNap	Brassica oleracea	F. culmorum, P. expansum	[128]
Snakins
Snakin Z	Jujube fruits	A. niger	[129]
SN1, SN2	Solanum tuberosum	F. solani, F. culmorum	[130]
StSN1-2	S. tuberosum	Fusarium spp., A. flavus	[131]
Thaumatin-like
Osmotin	N. tabacum	F. solani, F. oxysporum	[98]
Zeamatin	Zea mays	F. solani	[132]
Thionins
Pth-St1	S. tuberosum	F. solani	[133]
Thionin 2.4	Arabidopsis thaliana	F. graminearum	[134]
Tu-AMP1, AMP2	Tulipa gesneriana	F. oxysporum	[135]
Viscotoxin A3	Viscum album	F. solani	[136]
2S albumin
Bn-2S	Brassica napus	F. culmorum, F. oxysporum	[137]
CW-1	Malva parviflora	F. graminearum	[138]
Pe AFP1	Passiflora edulis	F. oxysporum	[139]
Pf2	P. edulis	F. oxysporum	[140]
LTPs
Bc-nsLTP	B. campestris	F. oxysporum	[141]
Ca-LTp1	Capsicum annuum	F. oxysporum	[142]
Ha-AP10	Helianthus annus	F. solani	[143]
Knottins
Mj AMP2	Mirabilis jalapa	F. oxysporum	[144]
PAFP-s	Phytolacca american	F. oxysporum, F. graminearum
Hairpinins
Sm-AMP-x2	Stellaria media	F.oxysporum, A. niger, A. alternata	[145]
Puroindolines
PIN-A	T. aestivum	F. culmorum	[146]
PIN-B	Hordeum vulgare	F. graminearum
Gly-rich peptides
Gc-GRP	Coffea canephora	F. oxysporum	[147]
Pg-AMP1	P. edulis	F. oxysporum	[148]

3.3. Antifungal AMPs from Animal Origin

Animal antifungal AMPs are produced at the sites that are constantly exposed to microbes, such as skin and mucosal barriers [149]. Various antifungal AMPs have been isolated from invertebrates and vertebrate species, including fish, amphibians, and mammals (Table 3). Several invertebrate AMPs display activity against mycotoxin-producing fungi, in particular Aspergillus and Fusarium species, and have been isolated from organisms such as scorpions, silk moth, fruit fly, mantis, bee, termites and ticks. Recently, the susceptibility of the AOH producer Alternaria brassicicola to thanatin, produced by the spined soldier bug Podisus maculiventris, was described [150]. An example of antifungal AMP from fish is pleurocidin, a cationic peptide isolated from the winter flounder Pleuronectes americanus, which showed antifungal activity against F. culmorum (DON, NIV and ZEA producer) and A. niger (OTA producer) [151]. Finally, mammalian antifungal AMPs are found in human and bovine, and show activity against a large list of mycotoxin-producing fungi including F. culmurum (DON, NIV, T-2 and ZON producer), P. expansum (PAT and CIT producer), A. niger (OTA producer), A. nidulans (ST), F. oxysporum (T-2 toxin, HT-2 toxin producer) and A. flavus (AFs producer).

Table 3.

Animal antifungal proteins and peptides with activity against mycotoxin-producing fungi.

Origin	Peptide	Target Fungi	Ref.
Invertebrate
Acanthoscurria gomesiana	Gomesin	Fusarium spp.	[156]
Bombyx mori	Cecropin A	Aspergillus spp., Fusarium spp.	[157]
Centruroides sculpturatus	BmKbpp2	F. culmorum	[158]
Drosophila melanogaster	Drosomycin	Fusarium spp., Aspergillus spp.	[159]
D. melanogaster	Metchnikowin	F. graminearum	[160]
Heliothis virescens	Heliomicin	Fusarium spp.	[161]
Ixodes ricinus	DefMT3, DefMT5, DefMT6	F. graminearum, F. culmorum	[162]
Opistophtalmus carinatus	Opistoporin-1	F. culmorum	[163]
Penaeid shrimps	Penaeidins	Aspergillus spp., F. oxysporum	[164]
Podisus maculiventris	Thanatin	A. brassicicola, F. culmorum	[150]
Pseudacanthotermes spiniger	Termicin/Spinigerin	Aspergillus spp., F. culmorum, F. oxysporym	[165]
Sphodromantis viridis	Mastoparan-S	F. culmorum, A. niger, A. fumigatus	[166]
Fish and Amphibians
Phyllomedusa bicolor	Skin-PYY	A. niger	[167]
Pleuronectes americanus	Pleurocidin	F. oxysporum, A. niger, Alternaria spp.	[151]
Mammals
Bovine	Cathelicidin BMAP-28	Aspergillus spp., Penicillium spp.	[168]
Bovine	Indolicidin	A. niger, Penicillium spp.	[169]
Bovine	Lactoferrin	A. niger	[153]
Human	Defensin HBD-3	F. culmorum, P. expansum, A. niger.	[152]
Human	Hepc20/Hepc25	A. niger	[170]
Human	Tritrptcin	A. flavus	[171]

Of note is the antifungal activity of the human β-defensin 3 (HBD-3) in cereal-based products. Application of 80 μg/mL delayed growth of F. culmorum, P. expansum and A. niger on bread after more than 13 days [152]. Antifungal functions of bovin lactoferrin and derived peptides have been also reported [153,154]. Different mycotoxin-producing fungi from Alternaria, Aspergillus, Penicillium and Fusarium were sensitive to lactoferrin-derived peptides. This report is interesting because lactoferrin has been designated by the United States Food and Drug Administration (FDA) as a GRAS food additive [155].

3.4. Synthetic Antifungal Peptides

The development of synthetic peptides has grown to overcome some drawbacks associated with natural peptides, including low antifungal activity, toxicity or instability. Synthetic AMPs that show antifungal properties against mycotoxin producers are listed in Table 4. This includes analogs of natural AMPs and de novo peptides together with information about the susceptible mycotoxin-producing fungi to these synthetic AMPs, which include different species from Aspergillus, Penicillium and Fusarium genera.

Table 4.

Synthetic antifungal peptides with activity against mycotoxin-producing fungi.

Peptide	Source	Target Fungi	Ref.
AGM182	Tachyplesin-derived	A. flavus	[39]
Di-K19Hc	Halocidin-derived	F. oxysporum, A. niger	[177]
D4E1	Cecropin-derived	Aspergillus spp., Fusarium spp.	[157,178]
γ-core	DefMT3, DefMT6, DefMT7-derived	F. graminearum, F. culmorum	[162,172]
K18M	Thanatin (8–21)-derived	F. culmorum	[179]
LfcinB17-31/LfcinB20-25	Lactoferricin-derived	A. nidulans, F. oxysporum, P. expansum, Alternaria spp.	[175]
MsrA1	Cecropin: Melittin -derived	F. solani	[180]
BP22	de novo	P. expansum	[181]
D-V13K	de novo	Aspergillus spp.	[182]
(KW)n/(RW)n	de novo	F. solani, F. oxysporum	[183]
O3TR/C12O3TR	de novo	F. culmorum, P. expansum, A. niger	[184]
PAF26/PAF32	de novo	Penicillium spp., F. oxysporum,	[75,175]
PAF76/PAF77	de novo	F. oxysporum	[185]
PEP 6	de novo	F. oxysporum	[185]
PPD1/66-10/77-3	de novo	A. flavus, A. parasiticus	[186]

Different strategies have been employed for developing analogs of AMPs. Natural proteins and peptides can be used for the design of novel synthetic bioactive peptides that are more potent than the original ones. They can derive from natural cleavage of natural proteins such as LfcinB17-31 and LfcinB20-25, which are derived from bovine lactoferrin [154]. Another strategy is to use the sequence of natural occurring AMPs as a template and design a new molecule. For instance, it has been shown that one of the functional regions of defensins is primarily located in the C-terminal β-sheet domain, called the γ-core motif. This is the case of the γ-core motif of the tick selected defensins (DefMT3, DefMT6, and DefMT7), which enhanced antifungal activity against F. graminearum and F. culmorum [162,172]. Another extensively used method is based on designing peptides that changes positive charge. In the peptide AGM182 the second disulfide linkage of tachyplesin1 has been replaced by a sequence that assumes an amphipathic β-sheet conformation with maximized positive charge density [39].

In addition to these analogs of AMPs, many synthetic peptides have been constructed via de novo synthesis such as a group of peptides, named PAFs, which have been designed using a combinatorial library [173,174,175]. Although these peptides were identified through a nonbiased approach, they show properties of natural AMPs. In fact, PAF26 has been proposed as a model peptide for the characterization and study of cationic, cell-penetrating antifungal peptides [176].

A good practical example of application is the tachyplesin1-derived peptide AGM182, which caused up to 72% reduction in A. flavus growth/infection after its expression in transgenic maize plants. Furthermore, reduced fungal growth in the AGM182 transgenic seeds resulted in a significant reduction in AF levels (76–98%) [31].

4. Effects of Distinct AMPs on Mycotoxin-Production

Inhibition of fungal growth could be a good strategy to avoid mycotoxin biosynthesis, but it is only possible if the fungal growth is minimized to a level in which fungi fail to produce mycotoxins. Currently there is evidence that antifungal AMPs also fulfill functions that affect the secondary metabolism such as mycotoxin biosynthesis, which adds a new dimension to the use of AMPs to control mycotoxin contamination. Here we describe antifungal AMPs from different origin that show anti-mycotoxigenic activity and their potential mechanisms of action. Table 5 summarizes antifungal AMPs that inhibit or reduce mycotoxin biosynthesis.

Table 5.

Fungal AMPs that exert a reduction or inhibitory effect on mycotoxin biosynthesis.

Origin	Peptide	Target Fungi	Mycotoxin Affected	Ref.
Bacteria
Achromobacter xylosoxidans	cyclo (L-leucyl-L-prolyl)	A. parasiticus	AFs	[187]
Bacilllus spp.	Iturin, fengycin and surfactin	A. parasiticus	AFB1	[193]
Bacillus spp.	Iturin A, surfactin	A. flavus, A. carbonarius	AFB1, OTA	[195]
B. megaterium	D1O/D1N/D2N	A. flavus	AFB1	[200]
B. subtilis	Iturin, fengycin and surfactin	A. flavus	AFB1	[191]
B. subtilis	Fengycin, surfactin	A. flavus	AFB1	[192]
B. subtilis	Iturin A	A. carbonarius	OTA	[196]
B. subtilis	Bacillomycin D	A. flavus	AFB1	[201]
B. velezensis		A. flavus, A. parasiticus, A. ochraceus	AFs, OTA	[194]
Lactobacillus paracasei	bacteriocin KC39	A. parasiticus, A. carbonarius	AFs, OTA	[190]
Senotrophomonas rhizophila	cyclo(Ala-Pro), cyclo(Val-Pro)	A. flavus, A. parasiticus	AFs	[175,176]
Fungi
Aspergillus giganteous	AFP	Fusarium spp.	DON	[202]
Penicillium chrysogenum	PgAfP	A. flavus	AFs	[81]
		A. carbonarius	OTA	[203]
		A. tenuissima	TeA, AOH, AME	[204]
Synthetic
DefMT3-derived	TC3	F. graminearum	DON, 15, 3-DON	[172]
de novo	PPD1/66-10/77-3	A. flavus, A. parasiticus	AFs	[186,205]
de novo	Small polypeptides	A. flavus	AFB1	[205]

Some peptides from bacteria are capable of inhibiting mycotoxin biosynthesis. The peptide cyclo (L-leucyl-L-prolyl), produced by Achromobaceter xylosoxidans, significantly inhibited AF production in A. parasiticus at low concentrations, and fungal growth at higher concentrations [187]. This peptide inhibited expression of aflR, a regulatory gene for aflatoxin biosynthesis. Likewise, peptides cyclo (L-Ala–L-Pro) and cyclo (L-Val–L-Pro) inhibited AF biosynthesis in A. flavus and A. parasíticus by inhibiting production of norsorolinic acid, an intermediate in the AF biosynthetic pathway and reducing the mRNA level of aflR gene [188]. Later, Limura et al. [189] investigated the mode of action of cyclo (L-Ala–L-Pro) and concluded that it inhibits AF production by affecting the detoxification enzyme glutathione S-transferase (GST), which plays an important role in the regulatory mechanism of AF production.

There is one report that explicitly describes anti-mycotoxin effects by AMPs from LAB strains. The bacteriocin KC39 from Lactobacillus paracasei showed anti-mycotoxigenic properties against A. parasiticus and A. carbonarius and their excreted mycotoxin AFs and OTA, respectively [190]. No mode of action is indicated or suggested in the report.

The Bacillus species have been reported to produce a wide spectrum of lipopeptides such as iturins, surfactins and fengycins, which have shown antifungal activity and effect on mycotoxin production. Several reports include antifungal activity of these lipopeptides against A. flavus, A. parasiticus and A. carbonarius, and inhibition or reduction of their respective mycotoxins (AFB1 and OTA) [191,192,193,194,195]. Additionally, Iturin A from Bacillus subtilis, significantly inhibited A. carbonarius growth and OTA production at concentrations of 10 μg/mL and 0.312 μg/mL, respectively [196]. These findings confirm that iturin A not only has a strong inhibitory effect on fungal growth, but also an effect on the synthesis of OTA depending on the peptide concentration. All these studies indicated that lipopeptides produced by Bacillus species show abilities to reduce both fungal growth and mycotoxin production. However, the mechanisms through which these lipopeptides exert their anti-mycotoxigenic activities are not well understood yet. Iturin and fengycin were shown to have the ability to bind to lipid layers and alter cell membrane structure and permeability [197,198]. On the other hand, the transcriptomic analysis carried out by Jiang et al. [196] indicated that iturin A inhibited fungi via multiple pathways, including effects on cell membrane and wall synthesis, osmotic pressure, energy metabolism, transportation and oxidation-reduction processes [196]. This study also suggests that iturin A reduces OTA production mainly by inhibiting the activity of cytochrome P450 and halogenase, two enzymes involved in OTA accumulation [199].

Bacillomycin D is another lipopeptide produced by B. subtilis that significantly affects mycelial growth and sporulation, and destabilizes the cell wall and cell membrane of A. flavus, reducing AF production [201]. Additionally, three peptides from Bacillus megaterium—L-Asp-L-Orn (D₁O), L-Asp-L-Asn (D₁N) and L-Asp-L-Asp-L-Asn (D₂N)—at concentrations ranging between 0.04 and 0.64 mg/mL, significantly inhibited AFB1 biosynthesis [200]. Authors showed that the regulatory genes aflR and aflS were highly downregulated when A. flavus was treated with these peptides. All in all, the three peptides strongly inhibited both the growth of A. flavus and AF production.

Several fungal AFPs have been reported to affect mycotoxin production, although in most cases the mechanisms through which these AFPs act on mycotoxin biosynthesis are not well understood. The AFP from A. giganteus has been employed in postharvest conservation. When sprayed on raw barley used in malt production, AFP inhibited the growth of F. graminearum, F. poae and F. sporotrichioides, and markedly reduced DON levels [202]. Authors suggested additional effects on the mycotoxin production apart from the antifungal activity. The effect of PgAFP from P. chrysogenum on mycotoxin accumulation by different fungi has also been described. First, PgAFP was able to retard the growth of A. flavus and decrease AF production [81]. PgAFP was also able to reduce OTA production by A. carbonarius [203] as well as TEA and AOH amounts synthesized by Alternaria tenuissima [206]. In contrast, PgAFP provoked an increase of PAT biosynthesis by P. expansum on an apple-based agar [84], as well as of AFs production by A. parasiticus in a low calcium culture medium [207]. Recently, it has been described that both the cell wall integrity pathway and the stress-related rho1 gene appear to be involved in the mode of action of PgAFP [206,208]. Finally, OTA production by A. niger did not vary when it was exposed to F. graminearum antifungal protein FgAFP, while AFB1 synthesis by A. flavus was increased [209]. These contradictory results could be due to a combination of factors affecting mycotoxin production (temperature, water availability, pH, light, nature of substrate, etc.), and highlight the necessity to conduct further studies to elucidate the mechanisms underlying the effects of AFPs on mycotoxin biosynthesis.

The role of AFPs on mycotoxin biosynthesis could be related to mechanisms of action beyond membrane permeabilization, such as ROS induction, or the inhibition of substrate acidification [210], which are two environmental factors with recognized modulating effect on the production of mycotoxins [211,212,213]. These findings show that under specific conditions, AFPs can be perceived as stress triggers for the initiation of mycotoxin production by the target fungi. Unfortunately, information about the potential of AFPs to prevent mycotoxin production is limited and contradictory. If increased mycotoxin production is a stress-related response in the presence of AFPs, the use of these compounds to control mycotoxin production must be carefully evaluated with a case-by-case approach.

There is also evidence that AFPs cover sensing/signaling functions, which may be of importance for the production of mycotoxins. The two more studied AFPs, A. giganteus AFP and P. chrysogenum PAF were associated with key transcriptional regulators for asexual development and secondary metabolism such as StuA and VelA [36,214,215]. P. chrysogenum Δpaf mutants resulted in a decrease of spore production compared to the wild type, which in many cases is correlated with the inhibition of mycotoxin production [216]. Moreover, expression of the A. giganteus afp gene is induced by several stress-related conditions such as nutrient starvation, excess NaCl, ethanol and heat shock [217]. Paege et al. [46] showed that expression of the A. niger AnAFP is involved in several cellular processes including secondary metabolism. Within secondary metabolism, up to 19 fungal genes were positively correlated with anafp expression. Some of them are involved in different mycotoxin biosynthesis pathways such as versicolorin reductase VerA, versicolorin A (AFs biosynthesis), p450 monooxygenase stcB (STE and AFs biosynthesis), STE synthesis transcription regulator aflR (AFs biosynthesis), O-methylsterigmatocystin oxidoreductase Ord1 (AFs biosynthesis), glutaminase A GtaA (OTA biosynthesis) polyketide synthase Fum5 (FUM biosynthesis), 15-decalonectrin 15-Oacetyltransferase Tri3 (trichothecene biosynthesis), AF biosynthesis regulator aflR (AFs pathway) and cytochrome P450 monooxygenase AvnA (AFs biosynthesis).

There are also some examples of non-natural synthetic peptides that affect mycotoxin production (Table 5). Four synthetic AMPs namely PPD1, 66-10, 77-3 and D4E1 at concentrations near MIC values were able to reduce AF production in A. flavus and A. parasiticus [186]. Quantitative real time polymerase chain reaction (RT-qPCR) analysis of the aflatoxin gene cluster showed that the aflR gene, and the downstream genes were significantly downregulated. The involvement of oxidative stress in the effect mediated by these peptides was also recently analyzed [218]. Results revealed that high peptide concentrations induced oxidative stress in A. flavus, while a complete inhibition of AF production was not observed, even though a four to five-fold reduction occurred. Another recent study with synthetic peptides showed inhibition of AF production, conidiation and sclerotia formation in A. flavus [205]. Furthermore, the expression of aflatoxin structural genes was significantly inhibited, and the intracellular ROS level reduced.

Finally, it has recently been shown that treatment with peptide TC3, which is a reduced form of the defensin DefMT3 γ-core motif, decreased F. graminearum growth and inhibited the production of the family type B trichothecenes (TCTB), including DON and its 15- or 3-acetylated forms (15- and 3-ADON) [172]. Its moderate impact on fungal growth and the high effect on mycotoxin production suggest that the mechanism of inhibition of toxin biosynthesis is independent of the antifungal effect. Authors additionally concluded that amino acid Lys6 plays a key role in its anti-mycotoxigenic activity. They also suggested that the mechanistic action of TC3 might be similar to that of the insect AMP metchnikowin from Drosophila melanogaster. This AMP has a potent activity against F. graminearum by inhibiting the activity of a key enzyme and other components of the tricarboxylic acid (TCA) cycle, γ-aminobutyric acid (GABA) shunt, and the electron transport chain [160,219], which are related to the TCTB biosynthesis pathway [160].

5. Future Perspectives

Despite the growing number of scientific reports on antimicrobial compounds to be applied in agriculture, postharvest and food, studies on real application of antifungal AMPs are still quite limited. Even more scarce are those applications directed to control mycotoxin production. Moreover, in the agrifood sector, each AMP must be subjected to a rigorous evaluation by regulatory agencies, such as the European Food Safety Authority (EFSA) or the FDA, before being recognized as safe (GRAS status). Hence, for further application of antifungal AMPs, there are still many challenges that remain to be faced. The commercial use of these molecules is hampered by the difficulties in their production; characteristics such as solubility, stability, or cytotoxicity, have to be improved; finally, AMPs must be active over time in complex matrices such as foods [37,42].

With respect to large scale production of AMPs, chemical synthesis is still too expensive, and the cost is not always affordable [73,113]. Moreover, production and purification of antifungal AMPs from natural sources have several limits, e.g., low peptide amounts [113]. Production of peptides by heterologous expression systems has become a rapidly expanding area of research, and relevant examples of antifungal AMPs produced in suit-able amounts in bacteria, yeast, filamentous fungi or plants have been reported [113,220,221]. The progress in the development of new production systems and fermentation processes will guarantee the production of stable, pure, and functional antifungal AMPs in quantities required for successful commercialization.

The activity of antifungal AMPs could be compromised of different characteristics of food matrices such as high concentration of salts [37,128]. Nevertheless, several natural antifungal AMPs are active in the presence of high salt concentrations and divalent cations [74,222]. Moreover, the efficacy of antifungal AMPs can be improved by means of structure stabilization, peptide concatemerization, and/or generation of peptide hybrid fusions [37,74]. Synthetic sequences derived from antifungal peptides have also been proved to improve their activities in food matrices [184,223]. AMPs can also benefit from combination with other fungicides agents or other control strategies that could enhance and improve their properties [77,224]. Additionally, delivery systems such as encapsulation or incorporation in biofilms may avoid proteolytic degradation or interaction with foods ingredients [225,226].

Finally, increasing knowledge about the structure-function relation of antifungal AMPs opens up new opportunities to improve their function on mycotoxin production and their (selective) antifungal activity, for example, by the substitution of single amino acids or the de novo synthesis of non-natural peptides. These approaches allow the development of synthetic peptides with greater antifungal and anti-mycotoxin activity, as well as characteristics such as reduced toxicity and stability, which are essential for their application as potential food preservatives [30,36]. The development of these synthetic peptides can be a good tool for the continuous fight against food spoilage and mycotoxin contamination.

6. Concluding Remarks

AMPs reviewed here are considered as possible solutions to the continuous existence of food spoilage and mycotoxin contamination, which are of topics of major concern. With the development of rapid resistance in fungi against fungicides, the ability of antifungal AMPs to invoke delayed resistance makes them potential antifungal agents. On the other hand, the increasing social demand for less processed and more natural food products while conserving their quality, safety, and shelf-life has raised the question of chemical preservative replacement. In this context, antifungal AMPs are natural alternatives of interest for their use in agriculture, postharvest and food as bioprotective tools to fight fungal spoilage and mycotoxin contamination, as well as to answer consumer demands and legislation. Due to their potency, broad-spectrum activity, different sources of availability in nature, lack of rapid development of resistance, low toxicity and fast killing activity, these proteins and peptides show several advantages over conventionally used fungicides and preservatives.

In this review, antifungal AMPs from different origins have been reported to show activity against common mycotoxin-producing fungi. Inhibiting fungal growth is often considered as the most effective strategy to prevent mycotoxin production. More importantly, in addition to their antifungal activity, AMPs display additional capabilities of reducing mycotoxin production, which makes them powerful tools to fight against food mycotoxin contamination. In this respect, antifungal AMPs from different origins and structures have been also reported in this review to show additional anti-mycotoxin functions. The mechanisms by which antifungal AMPs interact with mycotoxin production are varied and complex, ranging from the involvement of oxidative stress and the inhibition of substrate acidification to the specific inhibition of enzymatic components of the mycotoxin biosynthetic pathways. However, an increase of mycotoxin production has also been reported after the application of some antifungal AMPs. Therefore, their effect on mycotoxin biosynthesis must be carefully evaluated case-by-case. Overall, many more studies are needed to know the effect of the so far characterized antifungal AMPs in mycotoxin production.

All in all, the research presented in this review illustrates the potential for the application of AMPs to control mycotoxin-producing fungi and mycotoxin production. AMPs belong to a fast-growing scientific field and the identification of new sequences as well as the development of novel nature-inspired peptides active in different matrices is expected in the near future. Further advances in our understanding of the molecular events leading to the mode of action of AMPs will facilitate improvements in rational peptide design, aiding the development of new antifungals against mycotoxin producers based on AMP structures and mechanistic principles.

Author Contributions

Conceptualization, all authors; writing original draft preparation, P.V.M.-C., M.G. and S.G.; writing review and editing, all authors; visualization, all authors; supervision, all authors, funding acquisition, J.F.M. and P.M. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by grant RTI2018-101115B-C21 funded by MCIN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe”, PROMETEO/2018/066 from ‘Conselleria d’Educació’ (Generalitat Valenciana, Comunitat Valenciana, Spain).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.